Cargando…

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

Treatment with (neo)adjuvant chemotherapy for breast cancer, as currently given, causes cell damage by induction of double-strand DNA breaks. Because BRCA1 and BRCA2 proteins play a role in the repair of DNA damage, the efficacy of (neo)adjuvant chemotherapy may be increased in BRCA1/2-associated br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drooger, Jan C., Heemskerk-Gerritsen, Bernadette A. M., Smallenbroek, Nyrée, Epskamp, Cynthia, Seynaeve, Caroline M., Jager, Agnes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837227/ https://www.ncbi.nlm.nih.gov/pubmed/27060914 http://dx.doi.org/10.1007/s10549-016-3777-0

Ejemplares similares

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study
por: van Barele, Mark, et al.
Publicado: (2022)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
por: Whittemore, A S, et al.
Publicado: (2004)

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
por: Antoniou, A C, et al.
Publicado: (2002)

Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations
por: Dite, G S, et al.
Publicado: (2010)

Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment
por: Liede, Alexander, et al.
Publicado: (2017)

Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers
por: Evans, DG, et al.
Publicado: (2017)

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project
por: Hurtz, Hans-Jürgen, et al.
Publicado: (2017)

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014)

Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study
por: Son, Byung Ho, et al.
Publicado: (2012)

Author Reply: Decision-Making Management of Women with a High Risk of Developing Breast and Ovarian Cancer
por: Heemskerk-Gerritsen, Bernadette, et al.
Publicado: (2008)

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2007)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
por: Vliek, Sonja, et al.
Publicado: (2023)

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3
por: Hamdi, Yosr, et al.
Publicado: (2016)

Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study
por: West, Allison H., et al.
Publicado: (2019)

Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
por: Tacconi, Eliana MC, et al.
Publicado: (2017)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients
por: Park, Boyoung, et al.
Publicado: (2017)

A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing
por: Metcalfe, K A, et al.
Publicado: (2013)

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
por: Orsi, G., et al.
Publicado: (2021)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis
por: Pomerantz, Adi, et al.
Publicado: (2022)

Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
por: Ladan, Marjolijn M., et al.
Publicado: (2021)

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
por: Wang, Mingxing, et al.
Publicado: (2017)

A model of the BRCA1/BRCA2 network
por: Pujana, MA, et al.
Publicado: (2005)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

BRCA1 testing
por: Górski, Bohdan, et al.
Publicado: (2008)

Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature
por: Hu-Heimgartner, Ketty, et al.
Publicado: (2023)

The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
por: Kleeff, Jörg, et al.
Publicado: (2016)

The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer
por: van Barele, Mark, et al.
Publicado: (2020)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Epistatic Relationships in the BRCA1-BRCA2 Pathway
por: Scully, Ralph
Publicado: (2011)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity
por: Sajjad, Monique, et al.
Publicado: (2017)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t063c7pjcv909r8d9nj2cskr9t